308 related articles for article (PubMed ID: 16183853)
21. 6H,13H-Pyrazino[1,2-a;4,5-a']diindole analogs: probing the pharmacophore for allosteric ligands of muscarinic M2 receptors.
Zlotos DP; Tränkle C; Abdelrahman A; Gündisch D; Radacki K; Braunschweig H; Mohr K
Bioorg Med Chem Lett; 2006 Mar; 16(6):1481-5. PubMed ID: 16387499
[TBL] [Abstract][Full Text] [Related]
22. Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding.
Muth M; Bender W; Scharfenstein O; Holzgrabe U; Balatkova E; Tränkle C; Mohr K
J Med Chem; 2003 Mar; 46(6):1031-40. PubMed ID: 12620079
[TBL] [Abstract][Full Text] [Related]
23. Allosteric modulation of G-protein coupled receptors.
Jensen AA; Spalding TA
Eur J Pharm Sci; 2004 Mar; 21(4):407-20. PubMed ID: 14998571
[TBL] [Abstract][Full Text] [Related]
24. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures.
Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM
J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors.
Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC
Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965
[TBL] [Abstract][Full Text] [Related]
26. Muscarinic allosteric modulators: atypical structure-activity-relationships in bispyridinium-type compounds.
Sürig U; Gaal K; Kostenis E; Tränkle C; Mohr K; Holzgrabe U
Arch Pharm (Weinheim); 2006 Apr; 339(4):207-12. PubMed ID: 16572483
[TBL] [Abstract][Full Text] [Related]
27. Dualsteric GPCR targeting and functional selectivity: the paradigmatic M(2) muscarinic acetylcholine receptor.
Bock A; Mohr K
Drug Discov Today Technol; 2013; 10(2):e245-52. PubMed ID: 24050275
[TBL] [Abstract][Full Text] [Related]
28. Identification of various allosteric interaction sites on M1 muscarinic receptor using 125I-Met35-oxidized muscarinic toxin 7.
Fruchart-Gaillard C; Mourier G; Marquer C; Ménez A; Servent D
Mol Pharmacol; 2006 May; 69(5):1641-51. PubMed ID: 16439611
[TBL] [Abstract][Full Text] [Related]
29. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
Valant C; Sexton PM; Christopoulos A
Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
[TBL] [Abstract][Full Text] [Related]
30. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity.
Antony J; Kellershohn K; Mohr-Andrä M; Kebig A; Prilla S; Muth M; Heller E; Disingrini T; Dallanoce C; Bertoni S; Schrobang J; Tränkle C; Kostenis E; Christopoulos A; Höltje HD; Barocelli E; De Amici M; Holzgrabe U; Mohr K
FASEB J; 2009 Feb; 23(2):442-50. PubMed ID: 18842964
[TBL] [Abstract][Full Text] [Related]
31. G-protein-coupled receptor allosterism: the promise and the problem(s).
Christopoulos A; May LT; Avlani VA; Sexton PM
Biochem Soc Trans; 2004 Nov; 32(Pt 5):873-7. PubMed ID: 15494038
[TBL] [Abstract][Full Text] [Related]
32. Identification of multiple allosteric sites on the M1 muscarinic acetylcholine receptor.
Espinoza-Fonseca LM; Trujillo-Ferrara JG
FEBS Lett; 2005 Dec; 579(30):6726-32. PubMed ID: 16310776
[TBL] [Abstract][Full Text] [Related]
33. Mutational disruption of a conserved disulfide bond in muscarinic acetylcholine receptors attenuates positive homotropic cooperativity between multiple allosteric sites and has subtype-dependent effects on the affinities of muscarinic allosteric ligands.
Huang XP; Ellis J
Mol Pharmacol; 2007 Mar; 71(3):759-68. PubMed ID: 17132687
[TBL] [Abstract][Full Text] [Related]
34. Structure-based discovery of selective positive allosteric modulators of antagonists for the M
Korczynska M; Clark MJ; Valant C; Xu J; Moo EV; Albold S; Weiss DR; Torosyan H; Huang W; Kruse AC; Lyda BR; May LT; Baltos JA; Sexton PM; Kobilka BK; Christopoulos A; Shoichet BK; Sunahara RK
Proc Natl Acad Sci U S A; 2018 Mar; 115(10):E2419-E2428. PubMed ID: 29453275
[TBL] [Abstract][Full Text] [Related]
35. Structure-function studies of muscarinic acetylcholine receptors.
Leach K; Simms J; Sexton PM; Christopoulos A
Handb Exp Pharmacol; 2012; (208):29-48. PubMed ID: 22222693
[TBL] [Abstract][Full Text] [Related]
36. Allostery of atypical modulators at oligomeric G protein-coupled receptors.
Shivnaraine RV; Kelly B; Elmslie G; Huang XP; Dong YJ; Seidenberg M; Wells JW; Ellis J
Sci Rep; 2021 Apr; 11(1):9265. PubMed ID: 33927236
[TBL] [Abstract][Full Text] [Related]
37. Molecular modeling of the interaction of diagnostic radiopharmaceuticals with receptor proteins: m2 antagonist binding to the muscarinic m2 subtype receptor.
Kapp OH; Siemion J; Eckelman WC; Cohen VI; Reba RC
Recept Signal Transduct; 1997; 7(3):177-201. PubMed ID: 9440504
[TBL] [Abstract][Full Text] [Related]
38. Allosteric modulation in monomers and oligomers of a G protein-coupled receptor.
Shivnaraine RV; Kelly B; Sankar KS; Redka DS; Han YR; Huang F; Elmslie G; Pinto D; Li Y; Rocheleau JV; Gradinaru CC; Ellis J; Wells JW
Elife; 2016 May; 5():. PubMed ID: 27151542
[TBL] [Abstract][Full Text] [Related]
39. Probing the pharmacophore for allosteric ligands of muscarinic M2 receptors: SAR and QSAR studies in a series of bisquaternary salts of caracurine V and related ring systems.
Zlotos DP; Buller S; Stiefl N; Baumann K; Mohr K
J Med Chem; 2004 Jul; 47(14):3561-71. PubMed ID: 15214783
[TBL] [Abstract][Full Text] [Related]
40. G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms.
Bridges TM; Lindsley CW
ACS Chem Biol; 2008 Sep; 3(9):530-41. PubMed ID: 18652471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
